- In August 2024, Sound Pharmaceuticals aims to uphold its collaboration with WuXi AppTec for the production of its flagship Meniere’s disease medication, SPI-1005, despite the growing concerns regarding Chinese firms operating in the United States. The company recognizes the value of maintaining a reliable manufacturing partner to ensure the consistent supply of its drug. As the geopolitical landscape evolves, Sound Pharmaceuticals remains committed to navigating these challenges while continuing its vital partnership with WuXi AppTec
- In July 2024, Sound Pharmaceuticals announced positive results from its Phase 3 clinical trial evaluating SPI-1005 for the treatment of Meniere’s disease. The study demonstrated statistically significant improvements in patient outcomes, including reduced vertigo frequency and improved hearing stability. These findings support SPI-1005 as a promising therapeutic option, advancing it toward potential regulatory submission and commercialization
- In June 2024, Spiral Therapeutics announced the successful completion of its Phase 1b/2a clinical trial for SPT-2101 in Meniere’s disease. Presented at the 2024 AAO Annual Meeting, the data revealed that SPT-2101 was safe, well-tolerated, and showed promising efficacy signals in reducing vestibular symptoms. The results mark a significant milestone for Spiral Therapeutics in the advancement of inner ear drug delivery platforms
